Kymera Therapeutics (KYMR) announced its corporate goals for 2025, including anticipated progress on its clinical pipeline of immunology programs. KT-621 Phase 1 healthy volunteer trial ongoing, with data expected in 2Q25; Kymera plans to initiate a KT-621 Phase 1b trial in atopic dermatitis patients in 2Q25 with data in 4Q25 and plans to initiate parallel Phase 2b trials in AD and asthma in late 2025 and early 2026, respectively; KT-295 to advance into Phase 1 testing in 2Q25 with data expected in late 2025; KT-474/SAR444656 Phase 2b dose-ranging studies in hidradenitis suppurativa and AD ongoing, with completion expected in 1H26 and mid-2026, respectively; Novel oral immunology program with a first-in-class development candidate to be disclosed in 1H25; Well-capitalized with $8501 million in cash and runway into mid-2027
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal
- Capricor, Gilead, Kymera, Praxis among Oppenheimer’s top biotech picks for 2025
- Kymera Therapeutics initiated with a Buy at BTIG
- Kymera Therapeutics initiated with a Market Perform at BMO Capital
- Kymera Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo